TAVR—present, future, and challenges in developing countries
Transcatheter aortic valve replacement (TAVR) has become a well-established therapy for inoperable and high-risk patients of Aortic Stenosis in most of the part of the world. The technological advancements in the hemodynamic performance and design of valve prosthesis and also the data provided by various trials regarding the safety and efficacy of TAVR have widened the scope of TAVR in intermediate and low-risk groups also. The main focus of this review is to discuss the feasibility of TAVR in developing countries. Along with this review, it also gives a detailed outlook of the pros and cons of TAVR along with insight into the future of TAVR and its adoption into the low-risk group.
KeywordsTranscatheter aortic valve Para-valvular leak Bicuspid aortic valve
Compliance with ethical standards
Conflict of interest
The author declare that he has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Athappan G, Patvardhan E, Tuzcu EM, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013;61:1585–95. https://doi.org/10.1016/j.jacc.2013.01.047.CrossRefGoogle Scholar
- 7.George I, Guglielmetti LC, Bettinger N, et al. Aortic Valve Annular Sizing: Intraoperative Assessment Versus Preoperative Multidetector Computed Tomography. Circ Cardiovasc Imaging 2017;10. pii: e005968. https://doi.org/10.1161/CIRCIMAGING.116.005968.
- 10.Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37:2252–62. https://doi.org/10.1093/eurheartj/ehw112.CrossRefGoogle Scholar
- 12.Forrest JK. 30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System. Presented at: ACC 17. March 2017, Washington, DC, USA.Google Scholar
- 13.Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of Aortic Transcatheter Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60–9. https://doi.org/10.1016/j.jcin.2014.07.022.CrossRefGoogle Scholar
- 14.Bagur R, Rodés-Cabau J, Gurvitch R, et al. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv. 2012;5:540–51.CrossRefGoogle Scholar
- 18.Haussig S, Mangner N, Dwyer MG, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316:592–601. https://doi.org/10.1001/jama.2016.10302.CrossRefGoogle Scholar
- 26.Daubert MA, Weissman NJ, Hahn RT, et al. Long-term valve performance of TAVR and SAVR: a report from the PARTNER I trial. JACC Cardiovasc Imaging. 2016. https://doi.org/10.1016/j.jcmg.2016.11.004.
- 27.Reeves BC, Pike K, Rogers CA, et al. A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2). Health Technol Assess. 2016;20:1–260.Google Scholar
- 28.Généreux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63:1100–9. https://doi.org/10.1016/j.jacc.2013.10.058.CrossRefGoogle Scholar
- 32.Langer NB, Hamid NB, Nazif TM, et al. Injuries to the aorta, aortic annulus, and left ventricle during transcatheter aortic valve replacement: management and outcomes. Circ Cardiovasc Interv. 2017;10. pii: e004735. https://doi.org/10.1161/CIRCINTERVENTIONS.116.004735.
- 35.Ueshima D, Fovino LN, DÁmico G, Brener SJ, Esposito G, Tarantini G. Transcatheter versus surgical aortic valve replacement in low- and intermediate – risk patients : an updated systematic review and meta-analysis. Cardiovasc Interv Ther. 2018. https://doi.org/10.1007/s12928-018-0546-5.
- 44.Frost LJ, Reich MR. Creating access to health technologies in poor countries. In: Parker R, Sommer M, editors. Routledge handbook of global public health. New York: Routledge; 2011. chap. 36.Google Scholar
- 46.World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: WHO; 2007.Google Scholar
- 54.Stuart C. The lowdown on TAVR: as risk drops, expectations rise. Cardiovascular Business. Available at: http://www.cardiovascularbusiness.com/topics/structural-heart/lowdown-tavr-riskdrops-expectations-rise?nopaging¼1. Accessed 3 Apr 2016.
- 55.Mandrola J. TAVR costs put cardiologists in a tough spot. Medscape. Available at: www.medscape.com/viewarticle/856937. Accessed 3 Apr 2016.